A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

@article{Purtscher1994ABN,
  title={A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.},
  author={Martin Purtscher and Alexandra Trkola and Gerhard Gruber and Andrea Buchacher and Renate Predl and Franz Steindl and C Tauer and Rudolf Berger and Nicholas Barrett and Alois Jungbauer},
  journal={AIDS research and human retroviruses},
  year={1994},
  volume={10 12},
  pages={
          1651-8
        }
}
We have established a hybridoma clone, designated 2F5, secreting a neutralizing human monoclonal antibody (MAb) specific for gp41 of human immunodeficiency virus type 1 (HIV-1). The epitope of MAb 2F5 was mapped to amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala on the ectodomain of gp41. In this study different in vitro test systems were used to characterize the neutralizing properties of MAb 2F5. In syncytium inhibition assays, fusion inhibition experiments, and neutralization assays on different… 
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
TLDR
4E10 neutralizes potently not only tissue culture-adapted strains but also primary isolates of different clades, including A, B, C, D, and E, confirming that the region recognized by 2F5 and 4E10 is essential for viral infectivity and may be important for vaccine design.
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
TLDR
Human monoclonal antibody 2G12 to the gp120 surface glycoprotein of human immunodeficiency virus type 1 (HIV-1) potently and broadly neutralizes primary and T-cell line-adapted clade B strains of HIV-1 and inhibits syncytium formation in the AA-2 cell line.
Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody
TLDR
The results suggest that m14 is a novel CD4bs cross-reactive HIV-1-neutralizing antibody that exhibits a different inhibitory profile compared to the only known potent broadly neutralizingCD4bs human antibody, b12, and may have implications for the understanding of the mechanisms of immune evasion and for the development of inhibitors and vaccines.
Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41
TLDR
The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design.
Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
TLDR
Binding of polyclonal antisera and CL3 suggests that CL3 recognized a unique neutralizable core epitope, which was not immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits.
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
TLDR
The results suggest that this conserved B-cell epitope is a promising candidate for inclusion in a vaccine against AIDS and show that influenza virus can be used to effectively present the antigenic structure of this B- cell epitope.
Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.
TLDR
It is suggested that ELDKWA-specific antibodies induced by different antigenic formats show different neutralizing activities against HIV-1, which implies another complication in the development of effective vaccines.
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies
TLDR
Broadly neutralizing monoclonal antibodies are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design and have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade.
Expression, Purification, and In Vivo Administration of a Promising Anti-Idiotypic HIV-1 Vaccine
To date only a few neutralizing antibodies against HIV-1 exist. Since these neutralizing antibodies are only rarely found in sera of HIV-1 infected individuals an active vaccine is required. We
Monoclonal Antibodies Recognizing HIV-1 gp41 Could Inhibit Env-Mediated Syncytium Formation
Some monoclonal antibodies (mAbs) could inhibit infection by HIV-1. In this study, four mAbs against HIV-1 gp41 were prepared in mice. All four mAbs could bind to the recombinant soluble gp41 and
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
TLDR
This study used a human monoclonal antibody to the V3 domain with exceptionally potent and broad neutralizing activity against many diverse HIV-1 isolates and the anti-CD4-binding domain antibodies showed a more restricted pattern of activity.
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
TLDR
Since sequence variability of neutralizing epitopes is considered to be a major obstacle to HIV-1 vaccine development, the conserved B-cell epitope described here is a promising candidate for inclusion in a vaccine against AIDS.
Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I.
A human Epstein-Barr virus-transformed lymphoblastoid B-cell line was generated from peripheral blood mononuclear cells (PBMC) of an asymptomatic human immunodeficiency virus type I (HIV-1)
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody
TLDR
Characterization of the 15e epitope shows that it is conformation dependent and is distinct from previously recognized functional domains of gp120, suggesting that this epitope represents a novel site important for HIV-1 neutralization and CD4 binding.
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
TLDR
Results indicate that this conserved B-cell epitope of the HIV-1 envelope elicits a virus-neutralizing antibody response during natural infection in humans and may therefore be considered for inclusion in a vaccine against HIV- 1.
Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1.
TLDR
The Epstein-Barr virus immortalization technique was used to induce lymphoblastoid cell lines from peripheral blood lymphocytes of 10 people who were seropositive for HIV-1 and had no clinical symptoms, and a number of polyclonal lines were obtained which synthesized antibodies against most of the major proteins and glycoproteins of HIV- 1.
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
TLDR
A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.
Evaluation of monoclonal antibodies to HIV‐1 envelope by neutralization and binding assays: an international collaboration
TLDR
The relative potency (rank order) of the MAb in the panel were equivalent when determined by GMT or MNT, which may be useful to individual laboratories for estimating the sensitivity of their neutralization assays.
Neutralizing cross‐reactive and non‐neutralizing monoclonal antibodies to HIV‐1 gp 120
TLDR
Murine monoclonal antibodies characterized by their reactivity with the envelope precursor gp160 or the Escherichia coli recombinant DNA products pB1 and pE3 representing the carboxy- and amino-terminal halves of mature envelope gp120 induced neutralizing antibodies to HIV-1.
Characterization and large production of human monoclonal antibodies against the HIV‐1 envelope
TLDR
Peripheral blood lymphocytes from a volunteer immunized with a recombinant vaccinia virus VSC‐25 expressing the gp160 env protein of HTLV‐IIIB strain and from an asymptomatic HIV‐infected individual were immortalized by Epstein‐Barr (EBV), and monoclonal antibodies produced in large quantity in a hollow‐fibre reactor at defined culture conditions and purification procedures.
...
1
2
3
4
...